Security
BridgeBio Pharma, Inc. Common Stock · BBIO
BBIONASDAQCommon stockCurrentCIK 1743881Updated Oct 14, 2026
Name history
BridgeBio Pharma LLC · through May 16, 2019
BBIO price & chart
Loading TradingView…
NASDAQ:BBIO on TradingView ↗About the company
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
In the news
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 ↗
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of BridgeBio Pharma, Inc. (NASDAQ: BBIO) News provided by Purcell & Lefkowitz LLP Apr 23, 2025, 11:00 ET Share this article Share to X Share this article Share to X NEW YORK , April 23, 2025 /PRNewswire/ -- Purcell & Lefk ↗
Recent filings
Other Events
Items 8.01, 9.01
4 filing
Other Events
Items 8.01, 9.01
4 filing
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 936,025,000Source | 919,338,000Source | 546,380,000Source | 623,036,000Source |
| Property, Plant and Equipment, NetUSD | 5,366,000Source | 7,011,000Source | 11,816,000Source | 14,569,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 28,077,000Source | 23,926,000Source | 26,319,000Source | 28,712,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 570,119,000Source | 681,101,000Source | 375,935,000Source | 376,689,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 139,444,000Source | 4,722,000Source | — | — |
| Inventory, NetUSD | 26,753,000Source | — | — | — |
| Assets, CurrentUSD | 797,749,000Source | 720,692,000Source | 477,593,000Source | 548,853,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 44,070,000Source | 34,743,000Source | 24,305,000Source | 21,922,000Source |
| Operating Lease, Right-of-Use AssetUSD | 8,149,000Source | 5,767,000Source | 8,027,000Source | 10,678,000Source |
| Other Assets, NoncurrentUSD | 16,712,000Source | 18,195,000Source | 22,625,000Source | 20,224,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,012,606,000Source | 2,376,950,000Source | 1,888,915,000Source | 1,867,960,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 202,000Source | 196,000Source | 181,000Source | 157,000Source |
| Additional Paid in CapitalUSD | 2,057,646,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -3,821,194,000Source | -3,096,263,000Source | -2,560,501,000Source | -1,918,149,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 12,000Source | 8,000Source | 31,000Source | -328,000Source |
| Stockholders' Equity Attributable to ParentUSD | -2,086,610,000Source | -1,467,904,000Source | -1,354,257,000Source | -1,254,617,000Source |
| Additional Paid in Capital, Common StockUSD | — | 1,903,155,000Source | 1,481,032,000Source | 938,703,000Source |
| Liabilities and EquityUSD | 936,025,000Source | 919,338,000Source | 546,380,000Source | 623,036,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 287,971,000Source | 154,400,000Source | 143,844,000Source | 121,428,000Source |
| Operating Lease, Liability, CurrentUSD | 6,192,000Source | 4,506,000Source | 4,128,000Source | 3,675,000Source |
| Accounts Payable, CurrentUSD | 36,228,000Source | 9,618,000Source | 10,655,000Source | 11,558,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,811,000Source | 4,696,000Source | 8,981,000Source | 12,274,000Source |
| Other Liabilities, NoncurrentUSD | 244,000Source | 286,000Source | 9,361,000Source | 26,643,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 10,599,000Source | 10,150,000Source | 11,244,000Source | 11,282,000Source |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | — | 14,604,000Source | 6,096,000Source | 8,156,000Source |
| Deferred Revenue, NoncurrentUSD | — | 17,095,000Source | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 437,337,000Source | 446,445,000Source | 430,993,000Source |
| Redeemable Noncontrolling Interest, Equity, Carrying AmountUSD | -570,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -732,938,000Source | -543,347,000Source | -653,251,000Source | -484,652,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 5,434,000Source | 6,075,000Source | 6,494,000Source | 6,771,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 133,024,000Source | 95,800,000Source | 108,710,000Source | 91,559,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 134,722,000Source | 2,971,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 25,307,000Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | 26,609,000Source | 1,512,000Source | 2,780,000Source | -349,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -445,910,000Source | -520,726,000Source | -527,720,000Source | -419,494,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -24,487,000Source | 60,781,000Source | 54,033,000Source | 453,147,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,097,000Source | 933,000Source | 1,306,000Source | 4,821,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 14,226,000Source | 7,526,000Source | 6,880,000Source | 1,561,000Source |
| Payments for Repurchase of Common StockUSD | 48,276,000Source | — | 0Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 359,293,000Source | 748,457,000Source | 451,535,000Source | -13,134,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | 0Source | 0Source | 837,000Source |
| Repayments of Long-term DebtUSD | — | 473,417,000Source | 0Source | 20,486,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -111,104,000Source | 288,512,000Source | -22,152,000Source | 20,519,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 572,140,000Source | 683,244,000Source | 394,732,000Source | 416,884,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 43,670,000Source | 91,342,000Source | 61,108,000Source | 54,443,000Source |
| Income Taxes Paid, NetUSD | 1,198,000Source | — | — | — |
| Additional Financial Items | ||||
| Accretion ExpenseUSD | — | 15,763,000Source | 8,907,000Source | 8,570,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 136,882,000Source | 113,866,000Source | 115,016,000Source | 93,828,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 5,967,000Source | 3,761,000Source | 3,662,000Source | 3,568,000Source |
| Amortization of Intangible AssetsUSD | 2,700,000Source | 2,400,000Source | 2,400,000Source | 2,400,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source |
| Deconsolidation, Gain (Loss), AmountUSD | 0Source | 178,321,000Source | — | — |
| DepreciationUSD | 2,500,000Source | 3,700,000Source | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | 0Source | 8,136,000Source | 18,314,000Source | -8,222,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 0Source | 8,136,000Source | 8,668,000Source | 3,731,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | 0Source | 9,646,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | 0Source | 0Source | -6,261,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | -21,155,000Source | -26,590,000Source | 0Source | 0Source |
| Income (Loss) from Equity Method InvestmentsUSD | -72,608,000Source | -31,183,000Source | — | — |
| Income Tax Expense (Benefit)USD | 435,000Source | 1,153,000Source | — | — |
| InterestExpenseNonoperatingUSD | 53,103,000Source | 99,290,000Source | — | — |
| Investment Income, InterestUSD | 19,854,000Source | 17,249,000Source | 18,038,000Source | 7,542,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -8,007,000Source | -7,585,000Source | -10,049,000Source | -3,469,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -724,931,000Source | -535,762,000Source | -643,202,000Source | -481,183,000Source |
| Nonoperating Income (Expense)USD | -209,092,000Source | 50,779,000Source | -45,881,000Source | 27,550,000Source |
| Operating Lease, Impairment LossUSD | 0Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 43,058,000Source | 12,272,000Source | 17,370,000Source | -7,500,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 314,741,000Source | 144,049,000Source | 4,852,000Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | — | 0Source |
| Proceeds from (Payments to) Noncontrolling InterestsUSD | 2,150,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 27,735,000Source | 3,656,000Source | 6,008,000Source | 666,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 502,076,000Source | 221,902,000Source | 9,303,000Source | 77,648,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 531,225,000Source | 288,931,000Source | 150,590,000Source | 143,189,000Source |
| Operating Income (Loss)USD | -523,411,000Source | -592,973,000Source | -607,370,000Source | -512,202,000Source |
| Other Nonoperating Income (Expense)USD | 43,058,000Source | 12,272,000Source | 17,370,000Source | -7,500,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -732,503,000Source | -542,194,000Source | — | — |
| Income Tax Expense (Benefit)USD | 435,000Source | 1,153,000Source | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -8,007,000Source | -7,585,000Source | -10,049,000Source | -3,469,000Source |
| Earnings Per Share, BasicUSD per share | -3.78Source | -2.88Source | -3.95Source | -3.26Source |
| Earnings Per Share, DilutedUSD per share | -3.78Source | -2.88Source | -3.95Source | -3.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 191,527,482Source | 186,075,873Source | 162,791,511Source | 147,473,076Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 191,527,482Source | 186,075,873Source | 162,791,511Source | 147,473,076Source |
| Interest Expense (non-operating)USD | 53,103,000Source | 99,290,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,700,000Source | 2,400,000Source | 2,400,000Source | 2,400,000Source |
| Costs and ExpensesUSD | 1,025,487,000Source | 814,875,000Source | 616,673,000Source | 589,850,000Source |
| Current Income Tax Expense (Benefit)USD | 435,000Source | 1,153,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 4,100,000Source | 4,100,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | 0Source | 8,136,000Source | 8,668,000Source | 3,731,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -437,614,000Source | -207,795,000Source | -565,840,000Source | -485,079,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -72,608,000Source | -31,183,000Source | — | — |
| Interest ExpenseUSD | — | — | 81,289,000Source | 80,438,000Source |
| Interest Expense, DebtUSD | — | 34,330,000Source | 34,231,000Source | 34,137,000Source |
| Investment Income, InterestUSD | 19,854,000Source | 17,249,000Source | 18,038,000Source | 7,542,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -724,931,000Source | -535,762,000Source | -643,202,000Source | -481,183,000Source |
| Nonoperating Income (Expense)USD | -209,092,000Source | 50,779,000Source | -45,881,000Source | 27,550,000Source |
| Research and Development ExpenseUSD | 451,953,000Source | 506,461,000Source | 455,711,000Source | 399,462,000Source |
Offerings
Registration 333-297701
Registration 333-295678
Filing attachments
ef20083591_ex99-1.htm · 8-K · 2026-10-13
Exhibit 99.1 BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia - Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia - If approved, oral infigratinib would be the first and only approved oral therapy and a potential best-in-class treatment option…
Read attachment ↗ef20081330_ex99-1.htm · 8-K · 2026-08-31
EX-99.1 2 ef20081330_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans - This voluntary agreement expands access for Medicaid patients to BridgeBio’s currently marketed medicine and lowers drug costs for Americans without jeopardizing innovation and sustainability in rare diseases - BridgeBio will continue to offer Attruby via Medicare Part D without any future pricing mandates -…
Read attachment ↗ef20080234_ex99-1.htm · 8-K · 2026-08-17
EX-99.1 4 ef20080234_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder PALO ALTO, Calif., August 13, 2026 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockhol…
Read attachment ↗ef20080234_ex99-2.htm · 8-K · 2026-08-17
EX-99.2 5 ef20080234_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., August 14, 2026 - BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for g…
Read attachment ↗bbio-20260630xex991.htm · 8-K · 2026-08-10
EX-99.1 2 bbio-20260630xex991.htm EX-99.1 Document Exhibit 99.1 BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates - $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby - Attruby is the first ATTR-CM therapy associated with direct kidney protection, with post-hoc analyses published…
Read attachment ↗ny20078315x1_ex107.htm · S-3ASR · 2026-07-24
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BridgeBio Pharma, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount…
Read attachment ↗